Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

SAN DIEGO -- A novel therapy for polycythemia vera (PCV) maintained stable hematocrit levels for as long as 2.5 years and significantly reduced use of phlebotomy, a small randomized trial showed. The ...

Please provide your email address to receive an email when new articles are posted on . Induction therapy with twice-weekly rusfertide helped patients with polycythemia vera achieve target hematocrit ...

Credit: Thinkstock. The risk of hematocrit elevation may depend on testosterone therapy's route of administration, according to investigators. A rise in hematocrit levels occurs with 4 months of ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...

Cause of admission found to affect risk. SAN FRANCISCO—Dialysis patients hospitalized for infection, GI bleeding, or a major surgical procedure may experience a significant decline in hematocrit (Hct) ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

Fig.2 shows changes in hematocrit levels after administration of fEPO Full analysis set (FAS) : All subjects which fEPO was administered one or more times. Per Protocol Set (PPS) : All subjects in the ...